Sellas Life Sciences: Behind The Big Surge

2026-04-22 07:11:29 ET

Shares of cancer therapy concern Sellas Life Sciences Group, Inc. ( SLS ) have rallied more than 250% since a December 2025 low of $1.39 a share, as positive data from its two clinical assets have fortified investors. The market is eagerly awaiting the data-triggering 80th event from its Phase 3 trial (REGAL) for its lead asset GPS as a maintenance therapy for AML patients achieving a second complete remission. With chronic equity financings having raised the number of shares outstanding by 219% over the past two years and more dilution likely on the way, the recent rally in Sellas merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: